Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda joining 6 (IGLJ6) is a joining (J) gene segment within the immunoglobulin lambda light chain locus on human chromosome 22. J segments such as IGLJ6 are required for VJ recombination, the process that assembles variable (V), joining (J), and constant (C) gene segments to generate the diverse antigen-binding sites of the immunoglobulin lambda light chain. The IGLJ6 segment provides the J region of certain lambda light chains used in antibody assembly. There is no evidence that IGLJ6 corresponds to a direct therapeutic target or druggable receptor; rather, it is a germline sequence involved in immune repertoire development through somatic recombination in B cells. Note: - IGLJ6 is often annotated as an open reading frame (ORF) and may not even be functionally utilized in all individuals. - The IGLJ6 gene segment should not be confused with immunoglobulin lambda constant (IGLC6), lambda variable (IGLV6-57), or any receptor protein; its role is limited to immunoglobulin gene recombination as part of antibody genetic diversity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda joining 6 (IGLJ6).